Journal of Cancer Research and Therapeutics Close
 

Figure 4: Efficacy of knockdown of MDR1 in A2780 cells on its tumorigenicity and the sensitivity of chemotherapeutic agent paclitaxel in the tumor bearing nude mice. 5×106 no transfected A2780 cells and the A2780 cells stably transfected with the scrambled shRNA construct or the mock plasmids or the different MDR1-shRNA constructs were injected into flank of nude mice, respectively. (A to F) represent the A2780 cell group, the A2780 pSUPER-EGFP1 cells group, the A2780 scrambled shRNA cells group, the MDR1-shRNA1 cell group, the MDR1-shRNA2 cell group and the MDR1-shRNA3 cell group in order. Photos were pictured at 17 days after the different cells were injected into the mice and the formed tumors were pointed by arrows. (G) shows the tumor sizes after the tumor bearing nude mice were treated with paclitaxel. Signifi cant difference is indicated by asterisk (**) for P < 0.01, which represents the A2780 mDR1-shRNA 2 cells compared with the other cells, respectively

Figure 4: Efficacy of knockdown of MDR1 in A2780 cells on its tumorigenicity and the sensitivity of chemotherapeutic agent paclitaxel in the tumor bearing nude mice. 5×106 no transfected A2780 cells and the A2780 cells stably transfected with the scrambled shRNA construct or the mock plasmids or the different MDR1-shRNA constructs were
injected into flank of nude mice, respectively. (A to F) represent the A2780 cell group, the A2780 pSUPER-EGFP1 cells group, the A2780 scrambled shRNA cells group, the MDR1-shRNA1 cell group, the MDR1-shRNA2 cell group and the MDR1-shRNA3 cell group in order. Photos were pictured at 17 days after the different cells were injected into the mice and the formed tumors were pointed by arrows. (G) shows the tumor sizes after the tumor bearing nude mice were treated with paclitaxel. Signifi cant difference is indicated by asterisk (**) for <i>P</i> < 0.01, which represents the A2780 mDR1-shRNA 2 cells compared with the other cells, respectively